As a defective drugs attorney in Miami, I have read about the Actos cases proliferating in the Lafayette District Court in Louisiana. Actos is a prescription medication made by Takeda for use in the treatment of type 2 diabetes and has been linked to bladder cancer.


We defective drugs attorneys are currently investigating claims on behalf of individuals who have developed bladder cancer after using Actos. In each of these cases, we allege that people who have taken Actos face an increased risk for developing bladder cancer. In addition, we believe that Takeda concealed its knowledge of this risk and failed to provide adequate warnings to both the consumers and their doctors. Defendants deny all allegations of fault.

Defective drugs attorneys investigate the diabetes drug, Actos.
Defective drugs attorneys investigate the diabetes drug, Actos.


Defective drugs attorney cases from around the country have been consolidated into one proceeding in front of The Honorable Rebecca F. Doherty. This has been done to streamline what would otherwise be a very costly and confusing legal process if thousands of individual claims were pending in various courthouses in multiple state and federal jurisdictions.

The United States Judicial Panel on Multidistrict Litigation, or JPML, ordered on December 29, 2011 that all pending cases against Actos be transferred to the United States District Court for the Western District of Louisiana, and the JPML assigned Actos claims to Judge Doherty.

On July 16, 2013, Judge Doherty entered a comprehensive order regarding the scheduling of evidentiary hearings to determine the admissibility of the predicted expert testimony. She has set aside a considerable amount of the court’s time through the end of December 2013 and the first week in January 2014. To see the Court’s order, click here. Leer este artículo en español.


Meanwhile, as a defective drugs attorney, I am shocked to report that the FDA announced last week that it had approved the generic version of Actos, a startling endorsement in light of the ongoing legal war against Actos. The new generic will be available in 5-milligram, 30-mg and 45-mg tablets

Actos generic contains pioglitazone hydrochloride and has been used as a second-line treatment for type 2 diabetes by those who do not see sufficient results from first-line drugs, like metformin. Last year the FDA approved a generic version of the combination drug pioglitazone plus metformin (Actoplus Met), which contains a warning that it “may be associated with an increased risk of bladder cancer.”



The next Actos status conference is scheduled for August 22, 2013, in Louisiana, at 10:30 A.M. in open court. If you have a pending concern about your potential claim against Actos, I suggest that you contact our Actos lawyers today by emailing me, Spencer Aronfeld, or calling our office Toll Free at 866-597-4529 or at 305-441-0440 to preserve your legal rights and speak with a defective drugs attorney.

We are providing any Actos victim with a free initial consultation. We are accepting these cases on a contingency basis, which means you pay nothing up front and owe nothing if we are unable to resolve your case. Please call today.